Alzheimer's and Dementia

Journal

Publication Venue For

  • Daily stressful experiences, depressive symptoms, and behavioral responses of ADRD family caregivers.  16. 2020
  • Genetic origin of a large family with a novel PSEN1 mutation (Ile416Thr).  15:709. 2019
  • Transethnic genome-wide scan identifies novel Alzheimer's disease loci.  727-738. 2017
  • Genetically predicted body mass index and Alzheimer's disease-related phenotypes in three large samples: Mendelian randomization analyses.  11:1439-1451. 2015
  • Effect of APOE genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer's disease.  10:349-359. 2014
  • Implications of early treatment among Medicaid patients with Alzheimer's disease.  10:214-224. 2014
  • Frontotemporal degeneration, the next therapeutic frontier: Molecules and animal models for frontotemporal degeneration drug development.  9. 2013
  • The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: The next therapeutic frontier).  9:189-198. 2013
  • Estimating power with effect size versus slop differences: Both means and variance matter.  7:247-249. 2011
  • Requiring an amyloid-β1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials.  6:367-377. 2010
  • Brain metabolism differs in Alzheimer's disease and Parkinson's disease dementia.  4:421-427. 2008
  • Active lifestyles moderate clinical outcomes in autosomal dominant frontotemporal degeneration.  16:91.
  • Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpoint.  16:11-21.
  • Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpoint..  16:11-21.
  • Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration.  16:49-59.
  • Comparison of sporadic and familial behavioral variant frontotemporal dementia (FTD) in a North American cohort.  16:60-70.
  • Erratum: Estimating power with effect size versus slope differences: Both means and variance matter (Alzheimer's and Dementia (2011) 7 (247-249)).  7.
  • Genetic screening of a large series of North American sporadic and familial frontotemporal dementia cases.  16:118-130.
  • Glucose level decline precedes dementia in elderly African Americans with diabetes.  111-118.
  • Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration.  16:37-48.
  • Leisure-time physical activity sustained since midlife and preservation of cognitive function: The Atherosclerosis Risk in Communities Study.  15:273-281.
  • O3‐06‐01: Vascular amyloidosis impairs the gliovascular unit in a mouse model of Alzheimer's disease.  11.
  • Use of the CDR® plus NACC FTLD in mild FTLD: Data from the ARTFL/LEFFTDS consortium.  16:79-90.
  • Utility of the global CDR® plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium.  16:106-117.